[SYDNEY] Duality Biotherapeutics stock more than doubled on its Hong Kong debut on Tuesday (Apr 15), after the Chinese firm raised US$213 million in an initial public offering (IPO) launched the day financial markets reacted savagely to a US tariffs announcement.
The stock rose as high as HK$218 each, a gain of 130.4 per cent from its HK$94.60 issue price. Hong Kong’s Hang Seng Index was up 0.3 per cent in early trade.
Duality sold 17.33 million shares in its IPO at the bottom of a HK$94.60 to HK$103.20 indicative price range. It initially planned to sell 15.1 million shares but exercised an option to increase the number due to demand, regulatory filings showed.
Book-building started on Apr 7 when Hong Kong’s Hang Seng Index dropped 13 per cent, the benchmark’s worst one-day performance since 1997.
Duality is developing therapeutic drugs for cancer and autoimmune disease patients, its prospectus showed.
The majority of its products are unlikely to be subject to US import tariffs because of licensing agreements, analysts said. That contributed to the stock’s popularity, they said.
BT in your inbox
Start and end each day with the latest news stories and analyses delivered straight to your inbox.
“The success of the deal is a positive sign that when a deal has solid fundamentals, it will be able to garner interest in this volatile market,” said Aequitas Research analyst Ke Yan, who publishes on Smartkarma.
“It’s also an indication that international investors are returning to China.”
Eleven cornerstone investors from both China and abroad subscribed to US$65 million worth of Duality stock.
The IPO also attracted strong interest from retail and institutional investors, Duality’s filing showed, even at a time of global financial market turmoil.
Retail investors applied for 115 times the shares on offer, while the institutional portion was covered 13.5 times.
“Due to geopolitical conflict, investors are actually reassessing IPO prospects in the US which means Hong Kong IPOs could be more popular in the future,” said Criss Wang, an independent capital markets analyst.
Hong Kong’s Hang Seng Biotech Index is up 23.4 per cent so far this year versus 6.76 per cent for the Hang Seng Index. REUTERS
